Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 60 | 2021 | 4878 | 3.820 |
Why?
|
Neoplasms, Glandular and Epithelial | 9 | 2010 | 487 | 1.580 |
Why?
|
Genes, BRCA1 | 5 | 2011 | 764 | 0.940 |
Why?
|
Peritoneal Neoplasms | 7 | 2012 | 711 | 0.930 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 22 | 2019 | 11742 | 0.880 |
Why?
|
Periodicals as Topic | 5 | 2020 | 1463 | 0.870 |
Why?
|
Fallopian Tube Neoplasms | 5 | 2012 | 328 | 0.840 |
Why?
|
Platinum | 3 | 2019 | 220 | 0.780 |
Why?
|
Paclitaxel | 12 | 2011 | 1732 | 0.730 |
Why?
|
Evaluation Studies as Topic | 2 | 2013 | 1625 | 0.730 |
Why?
|
Colony-Stimulating Factors | 16 | 1991 | 218 | 0.640 |
Why?
|
Genes, BRCA2 | 3 | 2011 | 601 | 0.630 |
Why?
|
Editorial Policies | 2 | 2020 | 458 | 0.620 |
Why?
|
Genital Neoplasms, Female | 2 | 2019 | 532 | 0.600 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2010 | 326 | 0.590 |
Why?
|
Medical Oncology | 6 | 2019 | 2321 | 0.550 |
Why?
|
Organoplatinum Compounds | 6 | 2011 | 407 | 0.550 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 8002 | 0.530 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2019 | 9280 | 0.470 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2004 | 621 | 0.450 |
Why?
|
Peritoneum | 4 | 2011 | 225 | 0.450 |
Why?
|
Taxoids | 4 | 2004 | 668 | 0.430 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2007 | 478 | 0.430 |
Why?
|
Neoplasms | 11 | 2020 | 22173 | 0.420 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 5305 | 0.420 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13642 | 0.410 |
Why?
|
Carboplatin | 7 | 2023 | 794 | 0.380 |
Why?
|
Information Dissemination | 1 | 2019 | 1126 | 0.370 |
Why?
|
Carcinoma | 6 | 2011 | 2330 | 0.360 |
Why?
|
Growth Substances | 10 | 1990 | 768 | 0.360 |
Why?
|
Gene Expression Profiling | 6 | 2011 | 9420 | 0.340 |
Why?
|
Neoplasm Proteins | 6 | 2011 | 3617 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 1999 | 1406 | 0.340 |
Why?
|
Proto-Oncogene Proteins | 7 | 2001 | 4514 | 0.340 |
Why?
|
Informed Consent | 2 | 2007 | 1008 | 0.320 |
Why?
|
Cystadenocarcinoma, Papillary | 2 | 2001 | 56 | 0.320 |
Why?
|
Topotecan | 2 | 2007 | 132 | 0.320 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2011 | 373 | 0.310 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2009 | 629 | 0.300 |
Why?
|
Endometrial Neoplasms | 3 | 2019 | 1366 | 0.300 |
Why?
|
Tumor Cells, Cultured | 19 | 2000 | 6131 | 0.280 |
Why?
|
Angiogenesis Inhibitors | 4 | 2012 | 2048 | 0.280 |
Why?
|
Monocytes | 13 | 1992 | 2570 | 0.270 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 16 | 2000 | 891 | 0.270 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2011 | 3779 | 0.270 |
Why?
|
Intestinal Perforation | 1 | 2007 | 249 | 0.260 |
Why?
|
Female | 72 | 2021 | 392705 | 0.250 |
Why?
|
Microarray Analysis | 1 | 2008 | 750 | 0.250 |
Why?
|
Apoptosis | 5 | 1999 | 9490 | 0.250 |
Why?
|
Antibodies, Monoclonal | 14 | 2019 | 9177 | 0.250 |
Why?
|
Humans | 112 | 2023 | 761596 | 0.240 |
Why?
|
Treatment Outcome | 14 | 2019 | 64685 | 0.240 |
Why?
|
Granulocytes | 7 | 1988 | 551 | 0.240 |
Why?
|
Drug Administration Schedule | 9 | 2019 | 4853 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2011 | 8554 | 0.240 |
Why?
|
Cisplatin | 4 | 2011 | 1652 | 0.230 |
Why?
|
Receptors, Lymphocyte Homing | 2 | 1995 | 141 | 0.230 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2872 | 0.230 |
Why?
|
Publishing | 1 | 2011 | 833 | 0.220 |
Why?
|
Hematopoietic Stem Cells | 12 | 1992 | 3397 | 0.220 |
Why?
|
Deoxycytidine | 2 | 2010 | 877 | 0.220 |
Why?
|
Germ-Line Mutation | 3 | 2019 | 1858 | 0.200 |
Why?
|
Mullerian Ducts | 1 | 2003 | 203 | 0.200 |
Why?
|
Granulosa Cell Tumor | 1 | 2003 | 77 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5337 | 0.200 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1993 | 686 | 0.190 |
Why?
|
Patient Advocacy | 1 | 2004 | 360 | 0.190 |
Why?
|
Leukemia, Myeloid | 5 | 1991 | 694 | 0.190 |
Why?
|
Oncogenes | 3 | 2019 | 1222 | 0.190 |
Why?
|
Endpoint Determination | 1 | 2004 | 590 | 0.190 |
Why?
|
Cell Adhesion | 7 | 1999 | 3088 | 0.190 |
Why?
|
Gynecology | 1 | 2007 | 526 | 0.180 |
Why?
|
Cytarabine | 3 | 1993 | 698 | 0.180 |
Why?
|
Receptors, Cell Surface | 5 | 1995 | 2822 | 0.180 |
Why?
|
Prognosis | 13 | 2020 | 29629 | 0.180 |
Why?
|
Paraneoplastic Syndromes | 1 | 2001 | 155 | 0.170 |
Why?
|
bcl-2-Associated X Protein | 5 | 1999 | 282 | 0.170 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8527 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2004 | 857 | 0.170 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2011 | 217 | 0.170 |
Why?
|
Glycoproteins | 3 | 2003 | 2203 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 4 | 2019 | 17904 | 0.170 |
Why?
|
Maximum Tolerated Dose | 3 | 2010 | 883 | 0.160 |
Why?
|
Dermatomyositis | 1 | 2001 | 258 | 0.150 |
Why?
|
Infusions, Parenteral | 3 | 2011 | 397 | 0.140 |
Why?
|
Histocompatibility Antigens Class II | 3 | 1986 | 1435 | 0.140 |
Why?
|
Research Design | 3 | 2009 | 6180 | 0.140 |
Why?
|
Epithelium | 6 | 1999 | 1603 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 1997 | 2917 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 428 | 0.130 |
Why?
|
Integrins | 3 | 1995 | 834 | 0.130 |
Why?
|
Receptors, Cytoadhesin | 1 | 1995 | 8 | 0.130 |
Why?
|
Phthalazines | 1 | 2018 | 383 | 0.130 |
Why?
|
Tumor Stem Cell Assay | 3 | 1991 | 115 | 0.130 |
Why?
|
Cell Adhesion Molecules | 4 | 1994 | 1601 | 0.130 |
Why?
|
Neoplasm Staging | 8 | 2011 | 11120 | 0.130 |
Why?
|
Biopsy | 1 | 2007 | 6766 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2010 | 6815 | 0.120 |
Why?
|
Drug Interactions | 2 | 2010 | 1416 | 0.120 |
Why?
|
Survival Analysis | 8 | 2019 | 10090 | 0.120 |
Why?
|
Mutation | 4 | 2018 | 30053 | 0.120 |
Why?
|
Carrier Proteins | 3 | 1998 | 4937 | 0.120 |
Why?
|
Rectum | 1 | 2019 | 892 | 0.110 |
Why?
|
Platinum Compounds | 2 | 2010 | 95 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3688 | 0.110 |
Why?
|
Oligopeptides | 3 | 1995 | 1187 | 0.110 |
Why?
|
Indium Radioisotopes | 1 | 1993 | 113 | 0.110 |
Why?
|
Biological Products | 1 | 2003 | 914 | 0.110 |
Why?
|
Hysterectomy | 1 | 2019 | 857 | 0.110 |
Why?
|
RNA, Neoplasm | 2 | 2008 | 750 | 0.110 |
Why?
|
Pentetic Acid | 1 | 1993 | 209 | 0.110 |
Why?
|
Middle Aged | 26 | 2019 | 220921 | 0.110 |
Why?
|
Growth Inhibitors | 2 | 2003 | 378 | 0.110 |
Why?
|
Interleukin-3 | 5 | 1991 | 425 | 0.100 |
Why?
|
Signal Transduction | 6 | 2011 | 23447 | 0.100 |
Why?
|
DNA, Neoplasm | 3 | 2011 | 1745 | 0.100 |
Why?
|
Patient Selection | 1 | 2004 | 4244 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2009 | 10212 | 0.100 |
Why?
|
Ovary | 3 | 2004 | 959 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 1991 | 3615 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2004 | 3514 | 0.090 |
Why?
|
Interferon-gamma | 7 | 1989 | 3162 | 0.090 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1459 | 0.090 |
Why?
|
Erythroid Precursor Cells | 1 | 1992 | 211 | 0.090 |
Why?
|
Antigens, Neoplasm | 1 | 1999 | 1993 | 0.090 |
Why?
|
Injections, Intraperitoneal | 2 | 2003 | 413 | 0.090 |
Why?
|
Exonucleases | 1 | 2010 | 44 | 0.090 |
Why?
|
Ethics, Medical | 2 | 2007 | 783 | 0.090 |
Why?
|
Bone Marrow | 6 | 1993 | 2911 | 0.090 |
Why?
|
Transfection | 5 | 1998 | 5774 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 2 | 2011 | 6484 | 0.090 |
Why?
|
Aged | 20 | 2019 | 169310 | 0.090 |
Why?
|
Dioxoles | 1 | 2010 | 95 | 0.090 |
Why?
|
Interleukin-1 | 3 | 1989 | 1248 | 0.090 |
Why?
|
Tetrahydroisoquinolines | 1 | 2010 | 81 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2009 | 10766 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2735 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 1993 | 1972 | 0.080 |
Why?
|
Bone Marrow Cells | 4 | 1992 | 2417 | 0.080 |
Why?
|
Immunoenzyme Techniques | 3 | 2005 | 1704 | 0.080 |
Why?
|
Research | 1 | 1997 | 1982 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2004 | 11076 | 0.080 |
Why?
|
Blast Crisis | 1 | 1989 | 102 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2003 | 2020 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2508 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 1988 | 4352 | 0.080 |
Why?
|
DNA, Complementary | 2 | 2004 | 1991 | 0.080 |
Why?
|
Risk Factors | 9 | 2020 | 74213 | 0.080 |
Why?
|
Adult | 21 | 2019 | 221210 | 0.080 |
Why?
|
Collagen | 3 | 1995 | 2638 | 0.080 |
Why?
|
Cell Division | 7 | 1997 | 4465 | 0.080 |
Why?
|
Kidney | 1 | 2023 | 7048 | 0.070 |
Why?
|
Neoplastic Stem Cells | 2 | 1998 | 1351 | 0.070 |
Why?
|
Piperazines | 1 | 2018 | 2523 | 0.070 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 1990 | 431 | 0.070 |
Why?
|
Recombinant Proteins | 9 | 1996 | 6534 | 0.070 |
Why?
|
Receptors, Fibronectin | 2 | 1999 | 37 | 0.070 |
Why?
|
Benzenesulfonates | 1 | 2008 | 166 | 0.070 |
Why?
|
Receptors, Estrogen | 1 | 1996 | 2209 | 0.070 |
Why?
|
Immunotherapy | 1 | 2003 | 4652 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 617 | 0.070 |
Why?
|
Mass Screening | 1 | 2003 | 5429 | 0.070 |
Why?
|
Somatomedins | 1 | 2007 | 179 | 0.070 |
Why?
|
Etoposide | 2 | 2000 | 634 | 0.070 |
Why?
|
Histiocytes | 1 | 1987 | 98 | 0.070 |
Why?
|
Health Status | 1 | 2020 | 4077 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2010 | 646 | 0.070 |
Why?
|
Carcinosarcoma | 1 | 2007 | 106 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3537 | 0.070 |
Why?
|
Niacinamide | 1 | 2008 | 413 | 0.070 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.070 |
Why?
|
Alprostadil | 1 | 1986 | 86 | 0.070 |
Why?
|
Remission Induction | 2 | 2007 | 2397 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1642 | 0.060 |
Why?
|
bcl-X Protein | 2 | 1997 | 410 | 0.060 |
Why?
|
Phenylurea Compounds | 1 | 2008 | 529 | 0.060 |
Why?
|
Sequence Analysis, DNA | 2 | 2011 | 4740 | 0.060 |
Why?
|
Clone Cells | 4 | 1998 | 1659 | 0.060 |
Why?
|
Immunoblotting | 3 | 1997 | 1646 | 0.060 |
Why?
|
Colony-Forming Units Assay | 1 | 1985 | 352 | 0.060 |
Why?
|
Polyethylene Glycols | 1 | 2010 | 1189 | 0.060 |
Why?
|
DNA Mutational Analysis | 2 | 2011 | 4111 | 0.060 |
Why?
|
Tetradecanoylphorbol Acetate | 3 | 1991 | 817 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 1999 | 2016 | 0.060 |
Why?
|
Neutrophils | 4 | 1992 | 3767 | 0.060 |
Why?
|
Databases, Genetic | 1 | 2011 | 1742 | 0.060 |
Why?
|
Adenocarcinoma | 3 | 2001 | 6345 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 16990 | 0.060 |
Why?
|
Risk Assessment | 3 | 2020 | 23996 | 0.060 |
Why?
|
Postoperative Care | 2 | 2004 | 1468 | 0.060 |
Why?
|
Receptors, Colony-Stimulating Factor | 4 | 1990 | 50 | 0.060 |
Why?
|
Genomics | 1 | 2019 | 5821 | 0.050 |
Why?
|
Doxorubicin | 1 | 2010 | 2224 | 0.050 |
Why?
|
Mice, Nude | 3 | 1999 | 3614 | 0.050 |
Why?
|
Sirolimus | 1 | 2010 | 1533 | 0.050 |
Why?
|
Climacteric | 1 | 2003 | 57 | 0.050 |
Why?
|
Epithelial Cells | 3 | 2003 | 3677 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2010 | 5672 | 0.050 |
Why?
|
Quinazolines | 1 | 2009 | 1371 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2000 | 1351 | 0.050 |
Why?
|
Administration, Oral | 2 | 2009 | 4021 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2007 | 5247 | 0.050 |
Why?
|
Carcinoma, Endometrioid | 1 | 2005 | 276 | 0.050 |
Why?
|
Testicular Hormones | 1 | 2003 | 188 | 0.050 |
Why?
|
RNA Interference | 1 | 2011 | 2832 | 0.050 |
Why?
|
Inhibins | 1 | 2003 | 210 | 0.050 |
Why?
|
CA-125 Antigen | 1 | 2004 | 281 | 0.050 |
Why?
|
Specimen Handling | 1 | 2007 | 702 | 0.050 |
Why?
|
Ovariectomy | 1 | 2004 | 614 | 0.050 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1991 | 114 | 0.050 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3430 | 0.050 |
Why?
|
Back | 1 | 2001 | 64 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 3 | 1999 | 3733 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 1988 | 1844 | 0.050 |
Why?
|
SEER Program | 1 | 2007 | 1450 | 0.050 |
Why?
|
Forehead | 1 | 2001 | 75 | 0.050 |
Why?
|
Philadelphia Chromosome | 2 | 1993 | 117 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2010 | 2057 | 0.050 |
Why?
|
Quality of Life | 2 | 2018 | 13367 | 0.050 |
Why?
|
Drugs, Investigational | 1 | 2003 | 212 | 0.050 |
Why?
|
RNA, Messenger | 7 | 1998 | 12794 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2011 | 58984 | 0.050 |
Why?
|
Anti-Mullerian Hormone | 1 | 2003 | 407 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1996 | 4024 | 0.040 |
Why?
|
Survival Rate | 2 | 2005 | 12723 | 0.040 |
Why?
|
Receptors, Interleukin-2 | 4 | 1989 | 562 | 0.040 |
Why?
|
Cell Line | 9 | 1996 | 15601 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
Laparoscopy | 1 | 2011 | 2036 | 0.040 |
Why?
|
HLA-DR Antigens | 3 | 1986 | 602 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 1996 | 17635 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2004 | 1626 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8466 | 0.040 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2001 | 412 | 0.040 |
Why?
|
Cyclin D1 | 1 | 2001 | 451 | 0.040 |
Why?
|
T-Lymphocytes | 3 | 1994 | 10194 | 0.040 |
Why?
|
Lac Operon | 1 | 1999 | 237 | 0.040 |
Why?
|
bcl-Associated Death Protein | 1 | 1998 | 102 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2019 | 178 | 0.040 |
Why?
|
Thorax | 1 | 2001 | 555 | 0.040 |
Why?
|
Antigens, CD | 3 | 1995 | 4001 | 0.040 |
Why?
|
Ascitic Fluid | 1 | 1998 | 189 | 0.040 |
Why?
|
Interphase | 3 | 1989 | 228 | 0.040 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 1998 | 105 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2001 | 6075 | 0.040 |
Why?
|
Verapamil | 1 | 1998 | 242 | 0.040 |
Why?
|
beta-Galactosidase | 1 | 1999 | 574 | 0.040 |
Why?
|
Isoantigens | 1 | 2000 | 551 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 2 | 1992 | 829 | 0.040 |
Why?
|
Patient Participation | 1 | 2007 | 1445 | 0.040 |
Why?
|
Interleukin-2 | 4 | 1989 | 1889 | 0.040 |
Why?
|
Stem Cells | 2 | 1993 | 3524 | 0.040 |
Why?
|
Phosphorylation | 5 | 2001 | 8321 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2003 | 1784 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2004 | 15266 | 0.040 |
Why?
|
Adenoviruses, Human | 1 | 1999 | 255 | 0.040 |
Why?
|
Kinetics | 3 | 1996 | 6374 | 0.040 |
Why?
|
Receptors, Immunologic | 3 | 1990 | 1410 | 0.040 |
Why?
|
Vinblastine | 1 | 1998 | 488 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 858 | 0.030 |
Why?
|
Laparotomy | 1 | 1999 | 457 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12463 | 0.030 |
Why?
|
Laminin | 2 | 1995 | 408 | 0.030 |
Why?
|
Pyridines | 1 | 2008 | 2875 | 0.030 |
Why?
|
Neutropenia | 2 | 2000 | 885 | 0.030 |
Why?
|
Cyclophosphamide | 2 | 2000 | 2220 | 0.030 |
Why?
|
Tyrosine | 2 | 1991 | 1440 | 0.030 |
Why?
|
G1 Phase | 1 | 1997 | 403 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2001 | 1134 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2001 | 1154 | 0.030 |
Why?
|
Estradiol | 1 | 2003 | 1937 | 0.030 |
Why?
|
Receptors, Vitronectin | 1 | 1995 | 47 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1757 | 0.030 |
Why?
|
Hydroxyurea | 1 | 1996 | 284 | 0.030 |
Why?
|
Diaphragm | 1 | 1997 | 351 | 0.030 |
Why?
|
Peritoneal Cavity | 1 | 1995 | 135 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 1987 | 4431 | 0.030 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 1998 | 563 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1997 | 350 | 0.030 |
Why?
|
Amino Acid Sequence | 4 | 1996 | 13446 | 0.030 |
Why?
|
Endotoxins | 2 | 1988 | 520 | 0.030 |
Why?
|
Genetic Variation | 2 | 2019 | 6567 | 0.030 |
Why?
|
Genes, Reporter | 1 | 1999 | 1529 | 0.030 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 2 | 1992 | 48 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1997 | 478 | 0.030 |
Why?
|
Fibronectins | 2 | 1995 | 723 | 0.030 |
Why?
|
Vincristine | 1 | 1996 | 1036 | 0.030 |
Why?
|
Leukocyte Count | 4 | 1991 | 1596 | 0.030 |
Why?
|
Cell Separation | 4 | 1990 | 1720 | 0.030 |
Why?
|
Transcription, Genetic | 4 | 1995 | 7593 | 0.030 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 138 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 3 | 1991 | 2425 | 0.030 |
Why?
|
Hematopoiesis | 3 | 1988 | 2050 | 0.030 |
Why?
|
United States | 3 | 2019 | 72340 | 0.030 |
Why?
|
Vaginal Smears | 1 | 1996 | 499 | 0.030 |
Why?
|
Gene Expression Regulation | 3 | 1987 | 11904 | 0.030 |
Why?
|
Cytogenetics | 1 | 1993 | 198 | 0.030 |
Why?
|
Antigens, Surface | 2 | 1988 | 1606 | 0.030 |
Why?
|
Mice | 7 | 1999 | 81539 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2001 | 9610 | 0.030 |
Why?
|
Population Surveillance | 1 | 2003 | 2598 | 0.030 |
Why?
|
Infusion Pumps | 1 | 1993 | 163 | 0.030 |
Why?
|
Binding, Competitive | 2 | 1991 | 1141 | 0.030 |
Why?
|
Transplantation, Heterologous | 2 | 1998 | 2386 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1182 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 1994 | 691 | 0.020 |
Why?
|
Cations, Divalent | 1 | 1992 | 168 | 0.020 |
Why?
|
Microbial Collagenase | 1 | 1992 | 112 | 0.020 |
Why?
|
Staining and Labeling | 1 | 1996 | 1085 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 1993 | 233 | 0.020 |
Why?
|
Tamoxifen | 1 | 1996 | 965 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2001 | 2805 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2001 | 4243 | 0.020 |
Why?
|
Cell Communication | 2 | 1990 | 1657 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1994 | 1126 | 0.020 |
Why?
|
Models, Genetic | 2 | 2011 | 3442 | 0.020 |
Why?
|
Cell Survival | 2 | 1998 | 5791 | 0.020 |
Why?
|
Decision Making | 1 | 2004 | 3929 | 0.020 |
Why?
|
Protein Isoforms | 1 | 1995 | 1699 | 0.020 |
Why?
|
Cells, Cultured | 6 | 1989 | 18966 | 0.020 |
Why?
|
Cell Differentiation | 5 | 1990 | 11530 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 3 | 1996 | 2467 | 0.020 |
Why?
|
Hyaluronic Acid | 1 | 1993 | 483 | 0.020 |
Why?
|
Papillomaviridae | 1 | 1996 | 1119 | 0.020 |
Why?
|
S Phase | 1 | 1991 | 421 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1991 | 641 | 0.020 |
Why?
|
Genetic Vectors | 1 | 1999 | 3396 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 14665 | 0.020 |
Why?
|
Culture Media | 2 | 1990 | 897 | 0.020 |
Why?
|
Transcription Factors | 2 | 2001 | 12130 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 370 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2000 | 2747 | 0.020 |
Why?
|
DNA Repair | 1 | 1998 | 2046 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 1990 | 346 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2011 | 426 | 0.020 |
Why?
|
Acute Disease | 2 | 1991 | 7237 | 0.020 |
Why?
|
Animals | 9 | 1999 | 168475 | 0.020 |
Why?
|
Drug Resistance | 1 | 1994 | 1596 | 0.020 |
Why?
|
Cell Cycle | 1 | 1996 | 2932 | 0.020 |
Why?
|
Antibodies | 1 | 1996 | 2418 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1990 | 535 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 2000 | 5485 | 0.020 |
Why?
|
Leukopenia | 1 | 1988 | 213 | 0.020 |
Why?
|
Blood Cells | 1 | 1990 | 305 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1999 | 5790 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 1995 | 1726 | 0.020 |
Why?
|
Age Factors | 2 | 2003 | 18399 | 0.020 |
Why?
|
Cross-Linking Reagents | 1 | 1990 | 687 | 0.020 |
Why?
|
Cell Nucleus | 1 | 1996 | 2910 | 0.020 |
Why?
|
Palliative Care | 1 | 2002 | 3598 | 0.020 |
Why?
|
Complement System Proteins | 1 | 1990 | 735 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1991 | 951 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2001 | 12973 | 0.020 |
Why?
|
Suspensions | 1 | 1986 | 66 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1991 | 2217 | 0.020 |
Why?
|
Rosette Formation | 1 | 1985 | 152 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12059 | 0.020 |
Why?
|
Endocytosis | 1 | 1990 | 957 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 1988 | 909 | 0.020 |
Why?
|
Male | 8 | 2011 | 360846 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 1990 | 1125 | 0.020 |
Why?
|
Disease Progression | 1 | 2001 | 13510 | 0.010 |
Why?
|
Incidence | 1 | 2003 | 21355 | 0.010 |
Why?
|
Base Sequence | 1 | 1995 | 12441 | 0.010 |
Why?
|
Multigene Family | 1 | 2007 | 1076 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3810 | 0.010 |
Why?
|
Genes | 1 | 1987 | 1823 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 1991 | 1974 | 0.010 |
Why?
|
Lymphokines | 1 | 1985 | 927 | 0.010 |
Why?
|
Reference Values | 1 | 1990 | 4920 | 0.010 |
Why?
|
Down-Regulation | 1 | 1990 | 2919 | 0.010 |
Why?
|
Protein Binding | 1 | 1994 | 9353 | 0.010 |
Why?
|
Genetic Linkage | 1 | 2007 | 2341 | 0.010 |
Why?
|
Macrophages | 2 | 1987 | 5767 | 0.010 |
Why?
|
Vanadates | 2 | 1991 | 82 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 1551 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2000 | 321 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 1999 | 21019 | 0.010 |
Why?
|
Cell Fusion | 1 | 2000 | 294 | 0.010 |
Why?
|
Penetrance | 1 | 2001 | 383 | 0.010 |
Why?
|
Cytokines | 2 | 1991 | 7396 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 1640 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 2001 | 662 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 1 | 1998 | 197 | 0.010 |
Why?
|
Genome, Human | 1 | 2011 | 4425 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1997 | 5821 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1987 | 1405 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2001 | 1062 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41495 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2000 | 828 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2000 | 1341 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 1999 | 11122 | 0.010 |
Why?
|
Histocytological Preparation Techniques | 1 | 1996 | 33 | 0.010 |
Why?
|
CHO Cells | 1 | 1998 | 1387 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 1998 | 837 | 0.010 |
Why?
|
Escherichia coli | 1 | 1988 | 4217 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2000 | 1869 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2001 | 1115 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 1993 | 5672 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2011 | 80647 | 0.010 |
Why?
|
Models, Biological | 2 | 2007 | 9469 | 0.010 |
Why?
|
Cricetinae | 1 | 1998 | 2423 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1999 | 13381 | 0.010 |
Why?
|
Gene Frequency | 1 | 2001 | 3606 | 0.010 |
Why?
|
Leukapheresis | 1 | 1993 | 134 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2000 | 1784 | 0.010 |
Why?
|
Green Fluorescent Proteins | 1 | 1998 | 2065 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20100 | 0.010 |
Why?
|
Genetic Engineering | 1 | 1998 | 933 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2001 | 2457 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1989 | 7859 | 0.010 |
Why?
|
Cytoplasm | 1 | 1996 | 1510 | 0.010 |
Why?
|
Receptors, Interleukin-3 | 1 | 1990 | 29 | 0.010 |
Why?
|
Thymidine | 1 | 1991 | 299 | 0.010 |
Why?
|
Alleles | 1 | 2001 | 6864 | 0.010 |
Why?
|
BRCA1 Protein | 1 | 1996 | 1158 | 0.010 |
Why?
|
Biological Factors | 1 | 1990 | 157 | 0.010 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1991 | 329 | 0.010 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1991 | 457 | 0.000 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1998 | 2827 | 0.000 |
Why?
|
Cryopreservation | 1 | 1993 | 728 | 0.000 |
Why?
|
Bone Marrow Examination | 1 | 1988 | 155 | 0.000 |
Why?
|
Precipitin Tests | 1 | 1989 | 813 | 0.000 |
Why?
|
Erythrocyte Count | 1 | 1988 | 157 | 0.000 |
Why?
|
Methods | 1 | 1988 | 1067 | 0.000 |
Why?
|
Erythroblasts | 1 | 1988 | 142 | 0.000 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 1998 | 2898 | 0.000 |
Why?
|
Macrophage-1 Antigen | 1 | 1988 | 285 | 0.000 |
Why?
|
Blotting, Northern | 1 | 1989 | 1545 | 0.000 |
Why?
|
Adolescent | 3 | 2009 | 88326 | 0.000 |
Why?
|
Nucleic Acid Hybridization | 1 | 1988 | 1302 | 0.000 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 1741 | 0.000 |
Why?
|
Carcinoma, Renal Cell | 1 | 2001 | 3165 | 0.000 |
Why?
|
Platelet Count | 1 | 1988 | 781 | 0.000 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1988 | 629 | 0.000 |
Why?
|
Iodine Radioisotopes | 1 | 1989 | 1031 | 0.000 |
Why?
|
Kidney Neoplasms | 1 | 2001 | 4251 | 0.000 |
Why?
|
Epitopes | 1 | 1991 | 2503 | 0.000 |
Why?
|
DNA Replication | 1 | 1991 | 1418 | 0.000 |
Why?
|
Nuclear Proteins | 1 | 1998 | 5799 | 0.000 |
Why?
|
Rabbits | 1 | 1990 | 4772 | 0.000 |
Why?
|
Adjuvants, Immunologic | 1 | 1989 | 1036 | 0.000 |
Why?
|
Transplantation, Autologous | 1 | 1988 | 2115 | 0.000 |
Why?
|
Protein Conformation | 1 | 1991 | 3968 | 0.000 |
Why?
|
Ambulatory Care | 1 | 1993 | 2775 | 0.000 |
Why?
|
Leukemia | 1 | 1990 | 1522 | 0.000 |
Why?
|
Lipopolysaccharides | 1 | 1989 | 2206 | 0.000 |
Why?
|
Lymphoma | 1 | 1990 | 1901 | 0.000 |
Why?
|
Fever | 1 | 1988 | 1618 | 0.000 |
Why?
|
Peptides | 1 | 1991 | 4358 | 0.000 |
Why?
|
Drug Therapy, Combination | 1 | 1988 | 6312 | 0.000 |
Why?
|
Time Factors | 2 | 1990 | 39969 | 0.000 |
Why?
|
Sarcoma | 1 | 1988 | 1801 | 0.000 |
Why?
|
Multiple Myeloma | 1 | 1992 | 5146 | 0.000 |
Why?
|
Phenotype | 1 | 1990 | 16592 | 0.000 |
Why?
|
Proteins | 1 | 1986 | 6032 | 0.000 |
Why?
|